ADVISORY, Nov. 08, 2017 (GLOBE NEWSWIRE) --

What: 
InflaRX NV (Nasdaq:IFRX), a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) on November 8, 2017.

In honor of the occasion, Prof. Niels C. Riedemann, CEO & Founder, will ring the Opening Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:
Thursday, November 9, 2017 – 9:15 a.m. to 9:30 a.m. ET

InflaRX NV Media Contact:
MC Services AG
Katja Arnold / Shaun Brown / Dr. Cora Kaiser
Email: inflarx[at]mc-services.eu
Tel: +49-89-210 2280

Nasdaq MarketSite Media Contact:
Emily Pan
+1 (646) 441-5120
emily.pan@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About InflaRX NV
InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. The company is also developing additional molecules targeting chronic and inflammation-related diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. The team consists of renowned experts in complement and clinical research. InflaRx has been previously financed by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC, certain investment funds managed by a leading US investment management firm, bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group, Staidson Hongkong Investment Co Ltd, and various international family and industrial investment offices.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com   

-NDAQA-